• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

No Link Found Between HPV Vaccination and Primary Ovarian Insufficiency

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • An association between human papillomavirus (HPV) vaccination and primary ovarian insufficiency has been suggested but has not been confirmed in observational studies
  • Concerns about fertility are an impediment to vaccination uptake
  • Hviid et al. (JAMA Network Open, 2021) evaluated the risk of primary ovarian insufficiency after quadrivalent human papillomavirus (4HPV) vaccination

METHODS:

  • Retrospective cohort study
  • Participants
    • Danish-born girls and women
    • 11 to 34 years
    • Follow up from 2007 through 2016
  • Exposures
    • 4HPV vaccination
    • No vaccination
  • Study design
    • Cox proportional hazards regression was used to estimate hazard ratios (HRs) of primary ovarian insufficiency
    • Adjustments for age, calendar period
    • Propensity score was used to assess health care use, as increased interaction with healthcare system could lead to a greater likelihood of receiving a diagnosis
    • Additional analysis included: Follow-up following vaccination | Age at first vaccination | Calendar period at first vaccination (2007 to 2011 and 2012 to 2016)
  • Primary outcome
    • Hospital contacts for primary ovarian insufficiency
    • Rates of primary ovarian insufficiency
  • Secondary outcome
    • Secondary composite outcome of amenorrhea and oligomenorrhea

RESULTS:

  • 996,300 girls and women | 6,781,166 person-years of follow-up
    • 4HPV vaccinated: 50.8%
    • Unvaccinated: 49.2%
  • Primary ovarian insufficiency diagnoses
    • After 4HPV vaccination: 54
    • Unvaccinated: 90
  • Median (IQR) age of primary ovarian insufficiency diagnosis: 26.94 (12.68) years
  • No significant difference in risk for primary ovarian insufficiency with 4HPV vaccination
    • Adjusted HR 0.96 (95% CI, 0.55 to 1.68)
  • No association seen for secondary outcomes (composite amenorrhea and oligomenorrhea)
    • Adjusted HR 1.09 (95% CI, 0.97-1.22)

CONCLUSION:

  • There was no association between 4HPV vaccination and increased risk for primary ovarian insufficiency or amenorrhea/oligomenorrhea 
  • A limitation of this study is that primary ovarian insufficiency is a relatively rare finding in passive databases
  • The authors conclude

The HPV vaccines are cancer-preventing vaccines, and, thus, the lackluster uptake in many countries is disheartening

Our study provides much-needed support for the ovarian safety of the 4HPV vaccine, which is of key importance for clinical and public health personnel when addressing parental concerns about fertility issues associated with vaccination

There is currently little evidence for an association between 4HPV vaccination and primary ovarian insufficiency

On the contrary, the vaccine protects against infections that may decrease fertility 

Learn More – Primary Sources:

Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

HPV Vaccines: Cochrane Reviews Looks at the Evidence with Multi-Year Follow-Up
The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.
MMWR Update: The Impact of Vaccination on HPV Prevalence Among Young Women in the US
Beyond High-Risk Lesions: HPV Vaccination and Impact on Invasive Cervical Cancer Risk

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site